Progression of parkinsonism in multiple system atrophy
- PMID: 15654560
- DOI: 10.1007/s00415-005-0617-2
Progression of parkinsonism in multiple system atrophy
Abstract
Background: Progression of parkinsonian motor impairment is usually rapid and relentless in multiple system atrophy (MSA). However, it may also be subject to considerable variation. Prospective natural history studies using validated rating scales are required to accurately determine the progression of parkinsonism in MSA.
Objective: To assess the progression of parkinsonism in patients with the Parkinson variant of MSA.
Methods: Parkinsonian motor impairment was assessed on regular therapy at two time points (mean follow-up 11.8 months, SD 1.4) using the Hoehn and Yahr scale (H&Y), the Schwab and England ADL scale (SES) and the motor examination section of the UPDRS (UPDRS-III) in 38 patients with clinically probable MSA-P.
Results: We examined 38 patients with probable MSA-P (mean age 63.2 years, SD 7.4; mean disease duration 4.1 years, SD 3.0). The mean difference of UPDRS-III between baseline and follow-up was 10.8 (95% CI 8.6-12.9), consistent with an average annual 28.3 % increase of UPDRS-III baseline scores. Several variables were associated with faster progression of parkinsonism including low baseline global motor disability as assessed by H&Y and SES, low baseline UPDRS-III score, and short disease duration. UPDRS-III progression was unrelated to gender, age at symptom onset, and age at baseline visit.
Conclusion: This is the first observational study on UPDRS rates of decline in MSA. The observed 28.6% annual increase of UPDRS-III scores illustrates the rapid progression of motor impairment in MSA. Furthermore, motor progression appeared to be accelerated during the early disease stages. Our data allow sample size calculations that may be helpful for the planning of future therapeutic trials.
Similar articles
-
Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.Mov Disord. 2002 Jul;17(4):701-9. doi: 10.1002/mds.10171. Mov Disord. 2002. PMID: 12210859
-
Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).Mov Disord. 2006 Feb;21(2):179-86. doi: 10.1002/mds.20678. Mov Disord. 2006. PMID: 16161136
-
Comparison of gait parameters between drug-naïve patients diagnosed with multiple system atrophy with predominant parkinsonism and Parkinson's disease.Parkinsonism Relat Disord. 2019 Mar;60:87-91. doi: 10.1016/j.parkreldis.2018.09.018. Epub 2018 Sep 17. Parkinsonism Relat Disord. 2019. PMID: 30266299
-
The European Multiple System Atrophy-Study Group (EMSA-SG).J Neural Transm (Vienna). 2005 Dec;112(12):1677-86. doi: 10.1007/s00702-005-0328-y. Epub 2005 Jul 29. J Neural Transm (Vienna). 2005. PMID: 16049636 Review.
-
Does the Type of Multisystem Atrophy, Parkinsonism, or Cerebellar Ataxia Impact on the Nature of Sleep Disorders?Curr Neurol Neurosci Rep. 2016 Dec;16(12):105. doi: 10.1007/s11910-016-0704-z. Curr Neurol Neurosci Rep. 2016. PMID: 27844341 Review.
Cited by
-
Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale.PLoS One. 2011;6(8):e22293. doi: 10.1371/journal.pone.0022293. Epub 2011 Aug 4. PLoS One. 2011. PMID: 21829612 Free PMC article.
-
Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism.J Clin Neurol. 2022 May;18(3):259-270. doi: 10.3988/jcn.2022.18.3.259. J Clin Neurol. 2022. PMID: 35589315 Free PMC article. Review.
-
How to diagnose MSA early: the role of magnetic resonance imaging.J Neural Transm (Vienna). 2005 Dec;112(12):1625-34. doi: 10.1007/s00702-005-0332-2. Epub 2005 Jul 6. J Neural Transm (Vienna). 2005. PMID: 15997415 Review.
-
Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy.Exp Brain Res. 2010 Sep;206(1):1-13. doi: 10.1007/s00221-010-2312-5. Epub 2010 Jun 10. Exp Brain Res. 2010. PMID: 20821197
-
Nigrosome 1 visibility at susceptibility weighted 7T MRI-A dependable diagnostic marker for Parkinson's disease or merely an inconsistent, age-dependent imaging finding?PLoS One. 2017 Oct 10;12(10):e0185489. doi: 10.1371/journal.pone.0185489. eCollection 2017. PLoS One. 2017. PMID: 29016618 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources